Fundz

Alphyn Biologics, Inc. reported raising $2.17 Million in an initial SEC Form D filing, from an offering of $3.5 Million

PRIVATEMay 23, 2022$2.2M of $3.5M raised

Amount Raised

$2.17 Million

$2.17 Million sold, per SEC Form D (first sale May 23, 2022)

Round Type

Seed

AnnapolisBiotechnologyHealthcare

Quick answer

Alphyn Biologics raised $2.17 Million in a Seed round, dated May 23, 2022. Alphyn Biologics is based in Annapolis, Maryland, United States.

How much did Alphyn Biologics raise?
Alphyn Biologics raised $2.17 Million in a Seed round on May 23, 2022.
What does Alphyn Biologics do?
Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform.
Where is Alphyn Biologics based and how big is it?
Alphyn Biologics is based in Annapolis, Maryland, United States. Fundz records about 4 employees.
Who are the decision-makers at Alphyn Biologics?
Fundz holds 1 contact at Alphyn Biologics, including the President. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Alphyn Biologics that raised within 45 days of this round, from Fundz verified event records.

  • Kernal Biologics raised $25M (Series A) on July 7, 2022.
  • X4 Pharmaceuticals raised $56M on July 6, 2022.
  • AI Metrics raised $1.2M (Seed) on July 1, 2022.
  • Ascendia Pharmaceuticals raised $2.5M on July 1, 2022.
  • Sanara MedTech raised $16M on July 1, 2022.
  • Notable Labs, Inc. raised $10M on June 30, 2022.

Who to call at Alphyn Biologics, and when

A new round usually means Alphyn Biologics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Alphyn Biologics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Alphyn Biologics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Alphyn Biologics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Alphyn Biologics

Location

3724A THOMAS POINT ROAD

Annapolis, Maryland, United States

About

Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, currently in a Phase 2a clinical trial. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's bacterial and immune system components, making it ideal for treating infected and non-infected AD. Alphyn's AB-101 platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics with potential safety, efficacy, and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has a wholly owned subsidiary in Australia. We became operational in 2020 and have raised approximately $6.7 million.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Alphyn Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsSteven P., President hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Alphyn Biologics's next move

See what Strategic adds

Alphyn Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.